Frontage Holdings Corporation (HKG:1521)
1.200
+0.020 (1.69%)
Sep 11, 2026, 3:59 PM HKT
Frontage Holdings Revenue
Frontage Holdings had revenue of $148.19M USD in the half year ending June 30, 2026, with 15.35% growth. This brings the company's revenue in the last twelve months to $278.30M, up 10.00% year-over-year. In the year 2025, Frontage Holdings had annual revenue of $256.69M with 0.70% growth.
Revenue (ttm)
$278.30M
Revenue Growth
+10.00%
P/S Ratio
1.12
Revenue / Employee
$154.61K
Employees
1,800
Market Cap
2.44B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 256.69M | 1.78M | 0.70% |
| Dec 31, 2024 | 254.91M | -4.95M | -1.90% |
| Dec 31, 2023 | 259.86M | 9.50M | 3.79% |
| Dec 31, 2022 | 250.36M | 65.92M | 35.74% |
| Dec 31, 2021 | 184.44M | 58.63M | 46.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 2.20B |
| AIM Vaccine | 1.30B |
| Antengene Corporation | 652.54M |
| Medtide | 635.93M |
| BioDlink International Company | 582.45M |
| Laekna | 296.69M |
| Jiangsu Recbio Technology | 568.00K |
| Clover Biopharmaceuticals | 496.42K |